Ionis Pharmaceuticals (IONS) Total Liabilities (2009 - 2026)

Ionis Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 26.58% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 26.58% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 25.65% from the prior year.
• Total Liabilities declined to $3.0 billion in Q1 2026 per IONS's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $3.0 billion in Q4 2025 and bottomed at $1.8 billion in Q1 2022.
• The 5-year median for Total Liabilities is $2.4 billion (2024), against an average of $2.4 billion.
• Across the five-year window, Total Liabilities soared 43.28% in 2023 and fell 7.63% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $2.0 billion in 2022, then surged by 32.76% to $2.6 billion in 2023, then retreated by 7.22% to $2.4 billion in 2024, then increased by 25.65% to $3.0 billion in 2025, then decreased by 2.51% to $3.0 billion in 2026.
• Per Business Quant, the three latest IONS Total Liabilities figures stand at $3.0 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.4 billion (Q3 2025).